Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2018

Open Access 01-12-2018 | Short report

When do patient reported quality of life indicators become prognostic in breast cancer?

Authors: Chee Khoon Lee, Malcolm Hudson, John Simes, Karin Ribi, Jürg Bernhard, Alan S. Coates

Published in: Health and Quality of Life Outcomes | Issue 1/2018

Login to get access

Abstract

Background

Various patient reported quality-of-life indicators are independently prognostic for survival in metastatic breast cancer and other cancers. The same measures recorded at first diagnosis of early breast cancer carry no corresponding prognostic information. The present study aims to assess at what time in the disease evolution the prognostic association appears.

Methods

Among 8024 patients enrolled in one of seven randomized controlled trials in early-stage breast cancer 3247 had a breast cancer relapse after a median follow-up of 12.1 years. Of these 677 had completed QL indicator assessments within defined windows 1, 2 or 3 months prior to relapse. We performed Cox regression analyses using these assessments and using identical instruments after relapse. All analyses were stratified by trial and adjusted for baseline clinicopathologic factors.

Results

QL indicators in the months before relapse were not significantly prognostic for subsequent survival with the possibly chance exception of mood at the second month before relapse. After relapse, physical well-being was statistically significantly associated with survival (P < 0.001). This prognostic significance increased in later post-relapse assessments. Similar findings were observed using patient-reported indicators for nausea and vomiting, appetite, coping effort, and health perception.

Conclusions

Before cancer relapse, QL indicators were not generally prognostic for subsequent survival. After relapse, QL indicators substantially predicted OS, with a stronger association later in the course of relapsed disease. Simple patient perception of disease burden seems unlikely to explain this sudden change: rather the patient’s awareness of disease relapse must contribute.
Appendix
Available only for authorised users
Literature
1.
go back to reference Coates AS, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R, et al. Improving the quality of life in advanced breast cancer. A comparison of continuous and intermittent treatment strategies. N Engl J Med. 1987;317:1490–5.CrossRefPubMed Coates AS, Gebski V, Bishop JF, Jeal PN, Woods RL, Snyder R, et al. Improving the quality of life in advanced breast cancer. A comparison of continuous and intermittent treatment strategies. N Engl J Med. 1987;317:1490–5.CrossRefPubMed
2.
go back to reference Coates AS, Gebski V, Signorini D, Murray P, McNeil D, Byrne M, et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand breast cancer trials group [see comments]. J Clin Oncol. 1992;10:1833–8.CrossRefPubMed Coates AS, Gebski V, Signorini D, Murray P, McNeil D, Byrne M, et al. Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand breast cancer trials group [see comments]. J Clin Oncol. 1992;10:1833–8.CrossRefPubMed
3.
go back to reference Lee CK, Stockler MR, Coates AS, Gebski V, Lord SJ, Simes RJ. Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. Br J Cancer. 2010;102:1341–7.CrossRefPubMedPubMedCentral Lee CK, Stockler MR, Coates AS, Gebski V, Lord SJ, Simes RJ. Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. Br J Cancer. 2010;102:1341–7.CrossRefPubMedPubMedCentral
4.
go back to reference Smyth EN, Shen W, Bowman L, Peterson P, John W, Melemed A, et al. Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer. Health Qual Life Outcomes. 2016;14:52–64.CrossRefPubMedPubMedCentral Smyth EN, Shen W, Bowman L, Peterson P, John W, Melemed A, et al. Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer. Health Qual Life Outcomes. 2016;14:52–64.CrossRefPubMedPubMedCentral
5.
go back to reference Quinten C, Martinelli F, Coens C, Sprangers MA, Ringash J, Gotay C, et al. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer. 2014;120:302–11.CrossRefPubMed Quinten C, Martinelli F, Coens C, Sprangers MA, Ringash J, Gotay C, et al. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer. 2014;120:302–11.CrossRefPubMed
6.
go back to reference Coates AS, Thomson D, McLeod GR, Hersey P, Gill PG, Olver IN, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic melanoma. Eur J Cancer. 1993;29A:1731–4.CrossRefPubMed Coates AS, Thomson D, McLeod GR, Hersey P, Gill PG, Olver IN, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic melanoma. Eur J Cancer. 1993;29A:1731–4.CrossRefPubMed
7.
go back to reference Coates AS, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer. 1997;33:1025–30.CrossRefPubMed Coates AS, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer. 1997;33:1025–30.CrossRefPubMed
9.
go back to reference Coates AS, Hurny C, Peterson HF, Bernhard J, Castiglione-Gertsch M, Gelber RD, et al. Quality-of-life scores predict outcome in metastatic but not early breast cancer. J Clin Oncol. 2000;18:3768–74.CrossRefPubMed Coates AS, Hurny C, Peterson HF, Bernhard J, Castiglione-Gertsch M, Gelber RD, et al. Quality-of-life scores predict outcome in metastatic but not early breast cancer. J Clin Oncol. 2000;18:3768–74.CrossRefPubMed
10.
go back to reference Goodwin PJ, Ennis M, Bordeleau LJ, Pritchard KI, Trudeau ME, Koo J, et al. Health-related quality of life and psychosocial status in breast cancer prognosis: analysis of multiple variables. J Clin Oncol. 2004;22:4184–92.CrossRefPubMed Goodwin PJ, Ennis M, Bordeleau LJ, Pritchard KI, Trudeau ME, Koo J, et al. Health-related quality of life and psychosocial status in breast cancer prognosis: analysis of multiple variables. J Clin Oncol. 2004;22:4184–92.CrossRefPubMed
11.
go back to reference Efficace F, Therasse P, Piccart MJ, Coens C, Van Steen K, Welnicka-Jaskiewicz M, et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. J Clin Oncol. 2004;22:3381–8.CrossRefPubMed Efficace F, Therasse P, Piccart MJ, Coens C, Van Steen K, Welnicka-Jaskiewicz M, et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. J Clin Oncol. 2004;22:3381–8.CrossRefPubMed
12.
go back to reference Bredal IS, Sandvik L, Karesen R, Ekeberg O. Prognostic value of health-related quality-of-life parameters in early-stage breast cancer: an 8-year follow-up study. Psychooncology. 2011;20:1102–7.CrossRefPubMed Bredal IS, Sandvik L, Karesen R, Ekeberg O. Prognostic value of health-related quality-of-life parameters in early-stage breast cancer: an 8-year follow-up study. Psychooncology. 2011;20:1102–7.CrossRefPubMed
13.
go back to reference De Aguiar SS, Bergmann A, Mattos IE. Quality of life as a predictor of overall survival after breast cancer treatment. Qual Life Res. 2014;23:627–37.CrossRefPubMed De Aguiar SS, Bergmann A, Mattos IE. Quality of life as a predictor of overall survival after breast cancer treatment. Qual Life Res. 2014;23:627–37.CrossRefPubMed
14.
go back to reference Epplein M, Zheng Y, Zheng W, Chen Z, Gu K, Penson D, et al. Quality of life after breast cancer diagnosis and survival. J Clin Oncol. 2011;29:406–12.CrossRefPubMed Epplein M, Zheng Y, Zheng W, Chen Z, Gu K, Penson D, et al. Quality of life after breast cancer diagnosis and survival. J Clin Oncol. 2011;29:406–12.CrossRefPubMed
15.
go back to reference DiSipio T, Hayes S, Battistutta D, Newman B, Janda M. Patterns, correlates, and prognostic significance of quality of life following breast cancer. Psychooncology. 2011;20:1084–91.CrossRefPubMed DiSipio T, Hayes S, Battistutta D, Newman B, Janda M. Patterns, correlates, and prognostic significance of quality of life following breast cancer. Psychooncology. 2011;20:1084–91.CrossRefPubMed
16.
go back to reference Giese-Davis J, Collie K, Rancourt KM, Neri E, Kraemer HC, Spiegel D. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol. 2011;29:413–20.CrossRefPubMed Giese-Davis J, Collie K, Rancourt KM, Neri E, Kraemer HC, Spiegel D. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol. 2011;29:413–20.CrossRefPubMed
17.
go back to reference International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol. 1996;14:1885–93.CrossRef International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol. 1996;14:1885–93.CrossRef
18.
go back to reference International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol. 1997;15:1385–94.CrossRef International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol. 1997;15:1385–94.CrossRef
19.
go back to reference International Breast Cancer Study Group. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst. 2002;94:1054–65.CrossRef International Breast Cancer Study Group. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst. 2002;94:1054–65.CrossRef
20.
go back to reference International Breast Cancer Study Group. Adjuvant chemotherapy followed by Goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J NatlCancer Inst. 2003;95:1833–46. International Breast Cancer Study Group. Adjuvant chemotherapy followed by Goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J NatlCancer Inst. 2003;95:1833–46.
21.
go back to reference International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: international breast cancer study group trial 13-93. J Clin Oncol. 2006;24:1332–41.CrossRef International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: international breast cancer study group trial 13-93. J Clin Oncol. 2006;24:1332–41.CrossRef
22.
go back to reference Colleoni M, Gelber S, Simoncini E, Pagani O, Gelber RD, Price KN, et al. Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of international breast cancer study group (IBCSG) trials 13-93 and 14-93. Ann Oncol. 2007;18:1177–84.CrossRefPubMed Colleoni M, Gelber S, Simoncini E, Pagani O, Gelber RD, Price KN, et al. Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of international breast cancer study group (IBCSG) trials 13-93 and 14-93. Ann Oncol. 2007;18:1177–84.CrossRefPubMed
23.
go back to reference Basser RL, O'Neill A, Martinelli G, Green MD, Peccatori F, Cinieri S, et al. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of international breast cancer study group trial 15-95. J Clin Oncol. 2006;24:370–8.CrossRefPubMed Basser RL, O'Neill A, Martinelli G, Green MD, Peccatori F, Cinieri S, et al. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of international breast cancer study group trial 15-95. J Clin Oncol. 2006;24:370–8.CrossRefPubMed
24.
go back to reference Bernhard J, Hürny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, et al. Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The international breast cancer study group. Ann Oncol. 1997;8:825–35.CrossRefPubMed Bernhard J, Hürny C, Coates AS, Peterson HF, Castiglione-Gertsch M, Gelber RD, et al. Quality of life assessment in patients receiving adjuvant therapy for breast cancer: the IBCSG approach. The international breast cancer study group. Ann Oncol. 1997;8:825–35.CrossRefPubMed
25.
go back to reference Bernhard J, Sullivan M, Hurny C, Coates AS, Rudenstam CM. Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer. 2001;84:1156–65.CrossRefPubMedPubMedCentral Bernhard J, Sullivan M, Hurny C, Coates AS, Rudenstam CM. Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer. 2001;84:1156–65.CrossRefPubMedPubMedCentral
26.
go back to reference Butow PN, Coates AS, Dunn S, Bernhard J, Hürny C. On the receiving end. IV: validation of quality of life indicators. Ann Oncol. 1991;2:597–603.CrossRefPubMed Butow PN, Coates AS, Dunn S, Bernhard J, Hürny C. On the receiving end. IV: validation of quality of life indicators. Ann Oncol. 1991;2:597–603.CrossRefPubMed
27.
go back to reference Hürny C, Bernhard J, Bacchi M, van Wegberg B, Tomamichel M, Spek U, et al. The perceived adjustment to chronic illness scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Support Care Cancer. 1993;1:200–8.CrossRefPubMed Hürny C, Bernhard J, Bacchi M, van Wegberg B, Tomamichel M, Spek U, et al. The perceived adjustment to chronic illness scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Support Care Cancer. 1993;1:200–8.CrossRefPubMed
28.
go back to reference Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival: metastatic breast cancer. Ann Oncol. 2000;11:469–74.CrossRefPubMed Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival: metastatic breast cancer. Ann Oncol. 2000;11:469–74.CrossRefPubMed
29.
go back to reference Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival in metastatic melanoma. J Clin Oncol. 1999;17:2256–63.CrossRefPubMed Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival in metastatic melanoma. J Clin Oncol. 1999;17:2256–63.CrossRefPubMed
30.
go back to reference Ring L, Hofer S, Heuston F, Harris D, O'Boyle CA. Response shift masks the treatment impact on patient reported outcomes (PROs): the example of individual quality of life in edentulous patients. Health Qual Life Outcomes. 2005;3:55.CrossRefPubMedPubMedCentral Ring L, Hofer S, Heuston F, Harris D, O'Boyle CA. Response shift masks the treatment impact on patient reported outcomes (PROs): the example of individual quality of life in edentulous patients. Health Qual Life Outcomes. 2005;3:55.CrossRefPubMedPubMedCentral
31.
go back to reference Rees J, Clarke MG, Waldron D, O'Boyle C, Ewings P, MacDonagh RP. The measurement of response shift in patients with advanced prostate cancer and their partners. Health Qual Life Outcomes. 2005;3:21.CrossRefPubMedPubMedCentral Rees J, Clarke MG, Waldron D, O'Boyle C, Ewings P, MacDonagh RP. The measurement of response shift in patients with advanced prostate cancer and their partners. Health Qual Life Outcomes. 2005;3:21.CrossRefPubMedPubMedCentral
Metadata
Title
When do patient reported quality of life indicators become prognostic in breast cancer?
Authors
Chee Khoon Lee
Malcolm Hudson
John Simes
Karin Ribi
Jürg Bernhard
Alan S. Coates
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2018
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-017-0834-2

Other articles of this Issue 1/2018

Health and Quality of Life Outcomes 1/2018 Go to the issue